Trust in research is important but not well understood. We examine the ways that researchers understand and practice trust in research. Using a qualitative research design, we interviewed 19 researchers, including eight researchers involved in Australian Indigenous research. The project design focused on sensitive research including research involving vulnerable participants and sensitive research topics. Thematic analysis was used to analyze the data. We found that researchers’ understanding of trust integrates both the conceptual and concrete; researchers understand trust in terms of how it relates to other similar concepts and how they practice trust in research. This provides a sound basis to better understand trust in research, as well as identifying mechanisms to regain trust when it is lost in research.
Despite the central role of cytokines in mediating inflammation that underlies a range of childhood diseases, cytokine testing remains primarily limited to research settings and surrogate markers of inflammation are often used to inform clinical diagnostic and treatment decisions. There are currently no reference ranges available for cytokines in healthy children, either systemically (in blood) or at sites of disease (such as the lung). In our study, we aimed to develop an openly accessible dataset of cytokines in the airways and blood of healthy children spanning 1 to 16 years of age. We examined how cytokine concentration changes during childhood and assessed whether a core set of cytokine markers could be used to indirectly evaluate the response of a broad spectrum of inflammatory analytes. To develop our dataset, a total of 65 unique analytes were quantified in cell-free bronchoalveolar lavage (BAL) and plasma from 78 children. We showed that age profoundly impacts soluble immune analyte concentration in both sample types and identified a highly correlative core set of 10 analytes in BAL and 11 analytes in plasma capable of indirectly evaluating the response of up to 44 inflammatory mediators. This study addresses an urgent need to develop reference ranges for cytokines in healthy children to aid in diagnosis of disease, to determine eligibility for, and to monitor the effects of, cytokine-targeted monoclonal antibody therapy.
5 February 2025 in Transplantation and Cellular Therapy
An adaptive platform trial (APT) offers the ability to incorporate several research questions, in the same target population, across multiple domains (interventions), with the ability to add new questions in a perpetual manner. An APT is particularly appealing for paediatric haematopoietic stem cell transplant (HCT); an area of high heterogeneity, limited trial availability and high mortality. Ideally, all domains in an APT, would have the same primary endpoint. Therefore, an ordinal endpoint with multiple categories that combines various clinical outcomes into a single outcome measure is particularly appealing for APTs. Unfortunately there is no accepted ordinal endpoint for paediatric HCT trials. This paper aims to describe the methodology used to co-design a novel primary ordinal endpoint for the paediatric HCT APT - BANDICOOT. BANDICOOT is a study which aims to; "Build an Adaptive Novel platform Design: Improving the Complications, cost-effectiveness, Outcomes and Overall survival from haematopoietic stem cell transplant".The results of this process identified two potential ordinal endpoints that could be used, one focusing on organ support and the other on a combination of organ support, viral reactivation and immune reconstitution. We explored the data extraction required for these endpoints from electronic medical records which we will utilise to validate the endpoints and determine which will be used in the APT BANDICOOT. In an era where APT's are becoming increasingly utilised to answer important questions in clinical care, this article describes a reproducible strategy for the design of high quality and meaningful ordinal endpoints.
Suppurative lung disease and wheezing are common respiratory diseases of childhood, however due to poor understanding of underlying pathobiology, there are limited treatment options and disease recurrence is common. We aimed to profile the pulmonary and systemic immune response in children with wheeze and CSLD for identification of endotypes that can inform improved clinical management. We used clinical microbiology data, highly multiplexed flow cytometry and immunoassays to compare pulmonary (bronchoalveolar lavage (BAL)) and systemic immunity in children with lung disease and controls. Unsupervised analytical approaches were applied to BAL immune data to explore biological endotypes. We identified two endotypes that were analogous in both frequency and immune signature across both respiratory diseases. The hyper-inflammatory endotype had a 12-fold increase in neutrophil infiltration and upregulation of 14 soluble signatures associated with type 2 inflammation and cell recruitment to tissue. The non-inflammatory endotype was not significantly different to controls. We showed these endotypes are measurable in a clinical setting, and can be defined by measuring only three immune factors in BAL. We identified hyper-inflammatory and non-inflammatory endotypes common across paediatric wheeze and CSLD that, if validated in future studies, has the potential to inform clinical management.